Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Medimmune Llc patents


Recent patent applications related to Medimmune Llc. Medimmune Llc is listed as an Agent/Assignee. Note: Medimmune Llc may have other listings under different names/spellings. We're not affiliated with Medimmune Llc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medimmune Llc-related inventors


Binding molecules specific for asct2 and uses thereof

This disclosure provides asct2-binding molecules, e.g., anti-asct2 antibodies, and antigen-binding fragments thereof. In certain aspects, the asct2-binding molecules are conjugated to cytotoxic drugs, e.g., asct2 antibody-drug conjugates (adcs). ... Medimmune Llc

Compositions and methods for inhibiting cancer stem cells

The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (cscs) and may be used in the treatment of cancers associated with cscs, and particularly cancers and cscs that express lox1.. ... Medimmune Llc

Prediction of clinical response to il23-antagonists using il23 pathway biomarkers

The present invention relates to the use of components of the il23 pathway as biomarkers, e.g., il22, lcn2 and combinations thereof, to stratify or identify populations of patients suffering from il23-mediated diseases (e.g., crohn's disease) responsive to treatment with an anti-il23 antagonist (including, e.g., anti-il23 antibodies or antigen-binding fragments thereof). Levels of il23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an il23-mediated disease or disorder such a crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-il23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the il23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the il23-mediated disease with a specific therapeutic agent.. ... Medimmune Llc

Anti-rsv monoclonal antibody formulation

The present invention provides a formulation comprising: (i) an anti-rsv monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mm and the formulation has a ph of about 5.5 to about 7.5.. . ... Medimmune Llc

Prevention of n-terminal truncation in igg light chains

We discovered that recombinant antibody light chains having a murine secretory leader sequence and an sye motif at the n-terminus are truncated during post-translational processing. This disclosure provides two protein engineering solutions: to alter the sye amino acid sequence of the lc n-terminus to other alternatives; or to change the secretory leader peptide sequence. ... Medimmune Llc

Pyrrolobenzodiazepine-antibody conjugates

Conjugates of an antibody that binds to cd19 with pbd dimers.. . ... Medimmune Llc

Compositions and methods for treating cancer

The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (cscs) and may be used in the treatment of cancers associated with cscs, and particularly cancers and cscs that express ccl20 and/or ccr6.. ... Medimmune Llc

Human antibody molecules for il-13

Specific binding members, in particular human anti-il-13 antibody molecules and especially those which neutralize il-13 activity. Methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma.. ... Medimmune Llc

Stabilized liquid anti-rsv antibody formulations

The present invention provides liquid formulations of synagis® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (rsv) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of synagis® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of synagis® or an antigen-binding fragment thereof which immunospecifically binds to a rsv antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. ... Medimmune Llc

Targeted pyrrolobenzodiazapine conjugates

Provided are conjugate comprising pbds conjugated to a targeting agent and methods of using such pbds.. . ... Medimmune Llc

Compounds and methods for treating pain

. . This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an ngf antagonist and a tnfα antagonist. ... Medimmune Llc

Ctla-4 variants

Variants of cytotoxic t-lymphocyte antigen 4 (ctla-4) with high affinity, potency and stability. Formulations of ctla-4 variants at high concentration for subcutaneous or intravenous administration, e.g. ... Medimmune Llc

A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

The present invention provides isolated il-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against il-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.. ... Medimmune Llc

Binding molecules specific for cd73 and uses thereof

The present disclosure provides anti-cd73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with cd73-expression, e.g., cancer. ... Medimmune Llc

07/12/18 / #20180193480

Pyrrolobenzodiazepine-antibody conjugates

Conjugates of an antibody that binds to cd25 with pbd dimers.. . ... Medimmune Llc

06/28/18 / #20180179272

Novel assay to detect human periostin

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an il-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.. ... Medimmune Llc

06/21/18 / #20180169258

Pyrrolobenzodiazepine-anti-cd22 antibody conjugates

Conjugates of an isolated humanized, anti-cd22 antibody with pbd dimers.. . ... Medimmune Llc

06/21/18 / #20180169255

Conjugated compounds comprising cysteine-engineered antibodies

This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. ... Medimmune Llc

06/14/18 / #20180162936

Compounds

Binding members, e.g. Human antibody molecules, which bind interleukin-6 (il-6 ) and neutralise its biological effects. ... Medimmune Llc

06/14/18 / #20180162920

Protease-resistant lipidated glp-1 analogs

The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.. ... Medimmune Llc

06/07/18 / #20180155413

Neutralizing anti-influenza binding molecules and uses thereof

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza a virus and a second binding domain that specifically binds influenza b virus.. . ... Medimmune Llc

06/07/18 / #20180155409

Novel phage display library, members thereof and uses of the same

The present invention relates to a library (in particular a phage display library) from which an improved human antibody having greater specificity and potency for its target may be generated; and to methods of generating such a human antibody. In particular, the invention relates to a human antibodies against challenging targets obtainable from such a library and which have hcdr3s of at least 18 amino acids in length.. ... Medimmune Llc

05/31/18 / #20180147279

Combination therapy for non-small cell lung cancer positive for egfr mutation

The present invention features methods of treating lung cancer (e.g., nsclc) with an anti-pd-l1 antibody and a tyrosine kinase inhibitor in a subject identified as having an egfr mutation-positive tumor.. . ... Medimmune Llc

05/17/18 / #20180134717

Pyrrolobenzodiazepines and conjugates thereof

Conjugates and compounds for making conjugates which are pbd molecules linked via the n10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.. . ... Medimmune Llc

05/10/18 / #20180125973

Therapeutic combinations comprising anti-cd73 antibodies and uses thereof

The present invention provides therapeutic combinations featuring anti-cd73 antibodies (e.g., med19447) and a2a receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.. . ... Medimmune Llc

05/03/18 / #20180118839

Anti-ifnar1 antibodies with reduced fc ligand affinity

The invention provides anti-ifnar1 antibodies with reduced affinity for fc receptors and/or ligands and methods of making and using such antibodies.. . ... Medimmune Llc

05/03/18 / #20180117172

Site-specific antibody-drug conjugates

Site-specific anti-body-drug conjugates are described, in particular conjugates comprising an antibody, which binds her2 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Llc

04/19/18 / #20180105585

Antibodies to amyloid beta

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. ... Medimmune Llc

04/19/18 / #20180105575

Method of purifying albumin-fusion proteins

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. ... Medimmune Llc

04/12/18 / #20180099055

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds cd25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Llc

04/05/18 / #20180092986

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds cd19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Llc

04/05/18 / #20180092985

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Llc

03/29/18 / #20180085458

Methods for treating clostridium difficile infection and associated disease

The invention features methods for treating clostridium difficile infection (cdi), c. Difficile associated disease, and symptoms thereof, featuring the use of antibodies having enhanced half-life that specifically bind c. ... Medimmune Llc

03/22/18 / #20180079814

Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer

A method for treating lung cancer (e.g., non-small cell lung cancer) with an anti-pd-l1 antibody (medi4736), alone or in combination with an anti-ctla4 antibody (tremelimumab), in a patient identified using a polynucleotide marker of ifngamma.. . ... Medimmune Llc

03/15/18 / #20180072808

Humanized anti-ox40 antibodies and uses thereof

The disclosure provides humanized anti-ox40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.. ... Medimmune Llc

03/01/18 / #20180057605

Blood brain barrier transport molecules and uses thereof

The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.. ... Medimmune Llc

03/01/18 / #20180057596

Binding members of interleukin-4 receptor alpha (il4-ra)

Binding members, especially antibody molecules, for interleukin (il)-4 receptor alpha (il-4rα), and their therapeutic use e.g., in treating or preventing disorders associated with il-4rα, il-4 and/or il-13, examples of which are asthma and copd.. . ... Medimmune Llc

01/25/18 / #20180022807

Bispecific binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. ... Medimmune Llc

01/04/18 / #20180002411

Antibodies to alpha-synuclein and uses thereof

The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.. . ... Medimmune Llc

11/30/17 / #20170342121

Glucagon/glp-1 agonists for the treatment of obesity

This disclosure provides glp-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.. . ... Medimmune Llc

11/30/17 / #20170340752

Pyrrolobenzodiazepines and conjugates thereof

A conjugate of formula (a): wherein y is selected from formulae a1 and a2: z1 is a c1-3 alkylene group; z2 is a c1-3 alkylene group; q is: where qx is such that q is an amino-acid residue, a dipeptide residue or a tripeptide residue; l is a linker connected to a cell binding agent; cba is the cell binding agent; and n is an integer between 0 and 48.. . ... Medimmune Llc

11/23/17 / #20170333812

An improved manufacturing method

This application is directed to a method of producing vials containing a composition comprising a recombinant protein. In some embodiments, the method comprises: (a) providing a container containing a composition comprising a recombinant protein optionally where the container has been stored under positive pressure; (b) applying a vacuum to the container containing a composition comprising a recombinant protein; (c) allowing the vacuum to degas the composition; and (d) filling vials with the de gassed composition comprising a recombinant protein.. ... Medimmune Llc

11/16/17 / #20170327588

Cd40l-fc fusion polypeptides and methods of use thereof

Provided herein is a cd40l-fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the cd40l-fc fusion protein or the cd40l-fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-ctla4 antibody, anti-pd-l1 antibody).. . ... Medimmune Llc

11/09/17 / #20170320954

Therapeutic combinations and methods for treating neoplasia

The disclosure features a cxcr2 antagonist in combination with a checkpoint inhibitor (e.g., an anti-ctla-4 antibody or an anti-pd-l1 antibody) and methods of using the combination to enhance anti-tumor activity in a subject.. . ... Medimmune Llc

10/26/17 / #20170306381

Cell lines

. . There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses pylrs and trnapyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of trnapyl expression on cell viability and/or cell growth is reduced or eliminated.. . ... Medimmune Llc

10/26/17 / #20170306380

Amino acid derivatives

There are provided amino acid derivatives of formula v and vi as defined herein which are pyrrolysine analogs for use in bioconjugation processes.. . ... Medimmune Llc

10/26/17 / #20170306025

Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Provided herein are compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-pd-l1 antibody durvalumab (medi4736) and the anti-ctla-4 antibody tremelimumab are provided.. ... Medimmune Llc

10/26/17 / #20170304343

Binding proteins specific for lox1 and uses thereof

This disclosure provides lox1 (lox1) binding proteins such as anti-lox1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the lox1-binding proteins provided herein, inhibit, or antagonize lox1 activity. ... Medimmune Llc

10/05/17 / #20170281769

Stable anti-il-4ra formulation

. . The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-il4r antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/ml to about 200 mg/ml of an antibody or fragment thereof that specifically binds human interleukin-4 receptor alpha (hil-4rα), about 50 mm to about 400 mm of a viscosity modifier; about 0.002% to about 0.2% of a non-ionic surfactant; and a formulation buffer. ... Medimmune Llc

09/28/17 / #20170275347

Methods for identifying patients responsive to anti-pd-l1 antibody therapy

The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-pd-l1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: cxcl9, krt8, trim29, and/or ifngamma.. . ... Medimmune Llc

09/21/17 / #20170267780

Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties

The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an igg, constant domain, or fcrn binding fragment thereof (e.g., an fc region or hinge-fc region) (e.g., from a human iggi, e.g., human iggi), that have modifications of one or more of amino acid residues in at least the ch3 domain.. . ... Medimmune Llc

09/21/17 / #20170267778

Humanized anti-tn-muc1 antibodies and their conjugates

Humanized anti-tn-muc1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker to the antibody are described.. ... Medimmune Llc

09/14/17 / #20170260276

Treatment for rheumatoid arthritis

Treatment of rheumatoid arthritis (ra) to provide clinical benefit in patients, including decrease in das28-crp by more than 1.2 and/or improvement determined by acr20, acr50 or acr70, comprising administering therapeutic antibody mavrilimumab.. . ... Medimmune Llc

09/14/17 / #20170258934

Pyrrolobenzodiazepine-antibody conjugates

The present disclosure relates to the use of antibody-drug conjugates (adcs) comprising pyrrolobenzodiazepine (pbd) dimers and anti-cd25 antibodies for use in treating disorders characterized by the presence of cd25+ve cells.. . ... Medimmune Llc

08/24/17 / #20170239365

Pyrrolobenzodiazepines and conjugates thereof

A conjugate comprising a pbd dimer linked from the tether joining the two pbd units, wherein the linker is of formula (a1): (formula (a1)) wherein rn1 is selected from h and c1-4 alkyl; l is a linker connected to a cell binding agent; cba is the cell binding agent; n is an integer selected in the range of 0 to 48; q is: (formula (q)), where qx is such that q is an amino-acid residue, a dipeptide residue or a tripeptide residue.. . ... Medimmune Llc

08/10/17 / #20170226158

Intracellular antigen binding

The disclosure generally provides a designed ankyrin repeat protein (darpin) that specifically binds to an antigen, the darpin having an n-terminal cap section, at least two ankyrin repeat (ar) module sections, and a c-terminal cap section, characterized in that the darpin has a charge that is less negative than known 5 darpins. The disclosure also provides for generation of a library of the less negative darpins.. ... Medimmune Llc

07/20/17 / #20170204362

Cell culture methods and media comprising n-acetylcysteine

This application provides improved cell culture media and cell culture methods comprising n-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.. ... Medimmune Llc

06/29/17 / #20170183408

Antibody scaffold for homogenous conjugation

Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain where the native interchain cysteine amino acids have been replaced by amino acids having no thiol moiety.. ... Medimmune Llc

06/29/17 / #20170183397

Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof

This disclosure relates to combination therapies comprising anti-pseudomonas psl and pcrv bispecific binding molecules and related compositions, for use in prevention and treatment of pseudomonas infection.. . ... Medimmune Llc

06/22/17 / #20170174766

Antibody formulation

Herein described as liquid formulations of antibodies and biologically active fragments thereof that specifically bind to human icos polypeptide, exhibit increased in vivo adcc activity and undergo reversible self-association in solution.. . ... Medimmune Llc

06/22/17 / #20170174756

Stabilized angiopoietin-2 antibodies and uses thereof

Stabilized antibodies directed to angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.. ... Medimmune Llc

06/15/17 / #20170166634

Ion channel modulators and uses thereof

The invention provides antibodies that specifically bind a p2x4 polypeptide and modulate p2x4 channel activity, recombinant p2x4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-p2x4 antibodies, and methods of using p2x4 antibodies for the treatment of neuropathic pain and other indications.. . ... Medimmune Llc

05/18/17 / #20170137522

Targeted binding agents against b7-h1

Human monoclonal antibodies directed against b7-h1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of b7-h1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.. ... Medimmune Llc

05/11/17 / #20170129943

Treatment of polybacterial infections

Provided herein are methods of preventing and treating polybacterial infections comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope produced by at least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to staphylococcus aureus alpha toxin can be administered to a patient with a polybacterial infection comprising staphylococcus aureus and pseudomonas aeruginosa to inhibit the growth of pseudomonas aeruginosa.. ... Medimmune Llc

05/04/17 / #20170121771

Interferon alpha-induced pharmacodynamic markers and uses thereof

The present invention encompasses type-i ifn and ifnα-induced pd marker expression profiles, kits, and methods for identifying such ifnα-induced pd marker expression profiles. The type-i ifn and ifnα-induced pd marker expression profiles may also be used in, for example, methods of treating patients having a type-i ifn or ifnα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates ifnα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes ifnα activity, and in diagnosing or providing a prognosis to patients having ifnα-induced disorders.. ... Medimmune Llc

04/27/17 / #20170114151

Multispecific and multivalent binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.. ... Medimmune Llc

04/20/17 / #20170107291

Methods for treating chronic obstructive pulmonary disease using benralizumab

Provided herein is are methods of treating chronic obstructive pulmonary disease (copd) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.. . ... Medimmune Llc

04/20/17 / #20170106149

Single-use, self destructing shield for syringe needle

Disclosed are embodiments of a cap covering a needle on a syringe. The cap in the closed configuration is sized and dimensioned to cover the needle, and after the cap is removed from the needle the cap assumes an open configuration that is not readily usable to re-cap the needle.. ... Medimmune Llc

04/13/17 / #20170101468

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.. ... Medimmune Llc

03/30/17 / #20170088628

Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy

The invention provides compositions and methods featuring the use of mir-629 for identifying subjects responsive to b-cell depleting therapies (e.g., treatment with an anti-cd19 antibody). In other embodiments, the invention features the use of mir-629 to identify subjects as having a b cell malignancy.. ... Medimmune Llc

03/16/17 / #20170073397

Mrka polypeptides, antibodies, and uses thereof

The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject.. ... Medimmune Llc

03/16/17 / #20170073386

Gitrl fusion proteins and uses thereof

The disclosure provides gitrl fusion polypeptide subunits comprising an igg fc domain, a trimerization domain, and the receptor binding domain of gitr ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.. ... Medimmune Llc

02/23/17 / #20170051066

Stable anti-ifnar1 formulation

The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-infar1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/ml to about 200 mg/ml of an antibody or fragment thereof that specifically binds human interferon alpha 1 (infar1); about 20 mm to about 80 mm of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. ... Medimmune Llc

02/02/17 / #20170029499

Methods for treating hepcidin-mediated disorders

Methods for treating hepcidin-mediated disorders are provided.. . ... Medimmune Llc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Medimmune Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medimmune Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###